|
CN108025181A
|
|
For treating or preventing the composition for including 15-HEPE of cancer and neurological disease
|
|
US2016362358A1
|
|
Compositions comprising oxo-derivatives of fatty acids and methods of making and using same
|
|
WO2016113635A1
|
|
Compositions comprising 15-hepe and methods of using the same
|
|
CN107072959A
|
|
Medical composition comprising two high acid and gamma-linolenics (DGLA) with and application thereof
|
|
US2015290225A1
|
|
Compositions and methods of using same
|
|
US2015093344A1
|
|
Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof
|
|
US2015119593A1
|
|
Methods of making 15-hydroxy fatty acid derivatives
|
|
WO2015042442A1
|
|
Pharmaceutical compositions comprising dha, epa, and/or gla and an antibiotic agent and methods of use thereof
|
|
WO2014022816A2
|
|
Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same
|
|
US2014066507A1
|
|
Cosmetic compositions comprising EPA and salicylic acid and methods of making and using same
|
|
GB201307082D0
|
|
Pharmaceutical composition comprising 15-HETrE and methods of using the same
|
|
US2013267598A1
|
|
Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
|
|
GB201301626D0
|
|
Composition comprising 15-OHEPA and methods of using the same
|
|
GB201300628D0
|
|
Compositions comprising 15-OHEPA and methods of using the same
|
|
BR112014013098A2
|
|
compositions comprising fatty acids having 20 carbons and methods of producing and using them
|
|
CN104010637A
|
|
Pharmaceutical Compositions Comprising Dgla And/Or 15-HETrE And Methods Of Use Thereof
|
|
GB201213484D0
|
|
Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
|
|
GB201209344D0
|
|
Omega-6 Enriched PUFA Phospholipids
|
|
GB201207064D0
|
|
Pharmaceutical compositions comprising 15-hetre and methods of using the same
|
